Skip to main
GUTS

GUTS Stock Forecast & Price Target

GUTS Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Fractyl Health is a clinical stage metabolic therapeutics company with a novel approach to treating obesity and type 2 diabetes. The success of their lead product candidate, the Revita DMR System, has been demonstrated in both the REVEAL-1 and REVEAL-1 open-label extension (OLE) cohorts, with patients maintaining at least 5% of GLP-1-induced weight loss through one year. Fractyl's upcoming pivotal REMAIN-1 study is expected to further strengthen their position, with a mean total body weight loss of 18.3%. In addition, the company's RJVA-001 gene therapy for T2D has received CTA authorization in the Netherlands and is currently being evaluated in a Phase 1/2 clinical trial. With positive FDA feedback and the potential for accelerated coverage timelines via the RAPID pathway, Fractyl is positioned for success in the metabolic disease treatment market.

Bears say

Fractyl Health is projected to have a high chance of success in the weight maintenance market with its Revita program, and may see significant upside potential in both market penetration and geographic expansion opportunities. However, risks such as inconclusive clinical trials or funding difficulties could impede its progress towards commercialization. Initial findings for its trial data also appear promising with strong efficacy numbers, but a small sample size and shorter follow-up period may raise some concern. The positivity surrounding the company's potential is reflected in a Buy rating, but investors should remain cautious of potential risks.

GUTS has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fractyl Health Inc (GUTS) Forecast

Analysts have given GUTS a Buy based on their latest research and market trends.

According to 4 analysts, GUTS has a Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fractyl Health Inc (GUTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.